NEW: Premarket Now Starts at 4AM!

We’re excited to announce the extension of premarket and aftermarket hours! Our members now have access to quotes daily from 4:00 AM to 8:00 PM ET — offering greater flexibility and deeper insights into market trends beyond regular trading hours.

Upgrade to FINVIZ*Elite to access premarket quotes »

MTVA

MetaVia Inc

May 09 • 03:08PM ET

0.7059

Dollar change -0.0041
Percentage change -0.58	%

Healthcare • Biotechnology • USA • NASD

Held by: VTI VXF DFAS DFAT

Scroll to Statements

Index	-	P/E	-	EPS (ttm)	-4.32	Insider Own	63.65%	Shs Outstand	8.64M	Perf Week	-9.38%
Market Cap	7.12M	Forward P/E	-	EPS next Y	-1.58	Insider Trans	0.00%	Shs Float	3.67M	Perf Month	-48.85%
Income	-27.59M	PEG	-	EPS next Q	-0.39	Inst Own	8.98%	Short Float	1.94%	Perf Quarter	-59.20%
Sales	0.00M	P/S	-	EPS this Y	54.07%	Inst Trans	-29.45%	Short Ratio	0.14	Perf Half Y	-72.21%
Book/sh	0.92	P/B	0.77	EPS next Y	3.36%	ROA	-141.35%	Short Interest	0.07M	Perf Year	-81.62%
Cash/sh	1.59	P/C	0.44	EPS next 5Y	20.22%	ROE	-224.18%	52W Range	0.65 - 5.30	Perf YTD	-65.23%
Dividend Est.	-	P/FCF	-	EPS past 5Y	67.49%	ROI	-345.37%	52W High	-86.68%	Beta	0.20
Dividend TTM	-	Quick Ratio	1.94	Sales past 5Y	0.00%	Gross Margin	-	52W Low	9.10%	ATR (14)	0.12
Dividend Ex-Date	-	Current Ratio	1.94	EPS Y/Y TTM	-75.88%	Oper. Margin	-	RSI (14)	32.03	Volatility	11.00% 18.61%
Employees	9	Debt/Eq	0.02	Sales Y/Y TTM	-	Profit Margin	-	Recom	1.00	Target Price	15.50
Option/Short	No / Yes	LT Debt/Eq	0.01	EPS Q/Q	42.75%	Payout	-	Rel Volume	0.53	Prev Close	0.71
Sales Surprise	-	EPS Surprise	123.62%	Sales Q/Q	-	Earnings	Mar 20 BMO	Avg Volume	502.07K	Price	0.71
SMA20	-17.07%	SMA50	-43.40%	SMA200	-69.63%	Trades		Volume	231,739	Change	-0.58%

Date	Action	Analyst	Rating Change	Price Target Change
Dec-30-24	Initiated	H.C. Wainwright	Buy	$12

Today 08:01AM	MetaVia Announces $10.0 Million Private Placement Priced At-The-Market under Nasdaq Rules (PR Newswire)
May-07-25 02:00AM	MetaVia Presents Data on DA-1241, a GPR119 Agonist, Demonstrating Both Hepatoprotective and Glucose-Regulating Effects in Patients with Presumed MASH, at the EASL Congress 2025 (PR Newswire) -8.05%
Apr-23-25 08:31AM	MetaVia Announces Late-Breaking Poster Presentation on DA-1241 at the EASL Congress 2025 (PR Newswire) +8.40%
Apr-22-25 08:31AM	MetaVia Reports Additional Positive Top-Line Results From the MAD Part 2 of Its Phase 1 Study of DA-1726, a Novel 3:1 Ratio GLP-1 and Glucagon Dual Receptor Agonist to Treat Obesity, Further Demonstrating Its Best-In-Class Potential (PR Newswire)
Apr-15-25 07:01AM	MetaVia Announces Positive Top-Line Data From the 4-Week Phase 1 MAD Trial of DA-1726, a Novel 3:1 Ratio GLP-1 Glucagon Dual Receptor Agonist to Treat Obesity, Showing Compelling Weight Loss and Safety Effects With Potential Best-In-Class Glucose Control (GLP-1R), Waist Reduction (GCGR), and Tolerability (PR Newswire) -55.98%
07:31AM	Loading…
Mar-20-25 07:31AM	MetaVia Reports Year End 2024 Financial Results and Provides Corporate Update (PR Newswire)
Jan-10-25 08:05AM	MetaVia to Hold Advisory Committee Meeting at the 9th Annual MASH-TAG 2025 Conference (PR Newswire)
Dec-19-24 08:01AM	MetaVia to Participate in the 9th Annual MASH-TAG 2025 Conference After Releasing Positive Top-Line Results From Its Phase 2a Clinical Trial of DA-1241 in Patients with Presumed MASH (PR Newswire)
Dec-18-24 08:01AM	MetaVia Announces Positive Top-Line Results From Its Phase 2a Clinical Trial of DA-1241 in Patients with Presumed MASH (PR Newswire) -17.73%
Dec-04-24 07:00AM	Presenting on the Emerging Growth Conference 77 Day 2 on December 5th Register Now (GlobeNewswire)
Dec-03-24 03:45PM	Winter 2024 Investor Summit Virtual: Q4 Presentations Now Available for On-Demand Viewing (ACCESS Newswire)
07:00AM	Presenting on the Emerging Growth Conference 77 Day 1 on December 4th Register Now (GlobeNewswire)
Dec-02-24 08:01AM	MetaVia to Present at the Emerging Growth Conference in December (PR Newswire)

MetaVia, Inc. is a clinical-stage biotechnology company, which engages in developing and commercializing multi-modal disease-modifying therapies. Its pipeline includes ANA001, a proprietary oral niclosamide formulation, Gemcabene, which is assessed as an acute indication for COVID-19, NB-01, a treatment for painful diabetic neuropathy, and NB-02, which has the potential to treat the symptoms of cognitive impairment and modify the progression of neurodegenerative diseases. The company was founded on October 30, 2014 and is headquartered in Cambridge, MA.

open in yahoo | open in reuters | open in marketwatch | open in google | open in EDGAR

MTVA

MetaVia Inc

Upgrade your FINVIZ experience